Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57168 | 0.85 | ALDH1A1 (0.47) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL15061128 | 0.75 | ALDH1A1 (0.38) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL25312405 | 0.69 | — | — | |
| SCHEMBL25310855 | 0.69 | — | — | |
| SCHEMBL23522361 | 0.67 | MEN1 (0.35) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL21018280 | 0.67 | MEN1 (0.35) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL21896579 | 0.67 | MAPK1 (0.38) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL24070657 | 0.67 | BPTF (0.36) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL6512716 | 0.67 | TRPV4 (0.39) | MEN1ALDH1A1MAPTKMT2ATP53 | |
| SCHEMBL16747678 | 0.67 | ALDH1A1 (0.42) | MEN1ALDH1A1MAPTKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230229077-A1 | PHOTOACID GENERATOR FOR CHEMICALLY AMPLIFIED PHOTORESISTS FOR DEEP ULTRAVIOLET AND EXTREME ULTRAVIOLET LITHOGRAPHY | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2023-07-20 | — | — | US | claimed |
| US-20230229077-A1 | PHOTOACID GENERATOR FOR CHEMICALLY AMPLIFIED PHOTORESISTS FOR DEEP ULTRAVIOLET AND EXTREME ULTRAVIOLET LITHOGRAPHY | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230229077-A1 | PHOTOACID GENERATOR FOR CHEMICALLY AMPLIFIED PHOTORESISTS FOR DEEP ULTRAVIOLET AND EXTREME ULTRAVIOLET LITHOGRAPHY | PAG1, GABRP, PGLS | MEN1 4744/4885ALDH1A1 1489/4885MAPT 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.